Label-Free HLA Peptide Quantification via HPLC-MS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for quantifying MHC ligand peptides in primary tissue specimens are limited by their inability to handle varying tissue amounts and MHC expression levels, require beta2m-knockout cell lines, and are not scalable for high-throughput analysis, making them unsuitable for precise immunomonitoring and vaccine development.
Innovation Solution
A label-free method involving HPLC-MS analysis, allele-specific subgroup normalization, and data quality control to identify and quantify MHC ligand peptides in primary tissues, allowing for relative quantification and overpresentation scoring, which is applicable to primary human tissues and can be performed on a large scale.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If differential chemical labeling strategies are used for quantitation, then quantitation can be performed, but the scale of investigations is severely limited
Solution Approach 1:
The invention extracts and removes the chemical labeling step from the quantitation process. Instead of using differential chemical labeling, the method directly analyzes native peptides through HPLC-MS, eliminating the labeling bottleneck that limited investigation scale while maintaining quantitation precision through direct mass spectrometric measurement.
Solution Approach 2:
The invention replaces the mechanical/chemical labeling process with a direct analytical measurement system. HPLC-MS technology substitutes the chemical labeling strategy, enabling high-throughput analysis of multiple samples simultaneously without the time-consuming labeling steps, thus resolving the contradiction between precision and scale.
2Measurement precision
If all samples are processed within a single experiment, then quantitation can be performed, but the possible scale is severely limited
Solution Approach 1:
The invention segments the experiment into independent sample preparation and analysis phases. Each sample can be prepared and stored separately, then analyzed through standardized HPLC-MS protocols. This segmentation allows multiple samples to be processed in parallel across different experimental runs, eliminating the constraint of single-experiment processing while maintaining quantitation accuracy through internal standards and normalization.
Solution Approach 2:
The method performs preliminary sample preparation and storage before analysis. Samples are prepared in advance, stored under controlled conditions, and then analyzed when needed. This preliminary action decouples sample preparation from analysis, allowing flexible scheduling and scaling of investigations without compromising quantitation precision.
3Reliability
If MHC ligand peptides are isolated from primary tissue specimens, then relevant immunotherapy data can be obtained, but the analysis cannot be performed on a large scale
Solution Approach 1:
The invention replaces labor-intensive manual isolation and analysis methods with automated HPLC-MS systems. The mass spectrometry platform automatically identifies and quantifies MHC ligand peptides from prepared samples, eliminating manual bottlenecks and enabling high-throughput analysis of primary tissue specimens while maintaining the reliability needed for immunomonitoring.
Solution Approach 2:
The method changes the analytical parameters by using mass spectrometry detection instead of traditional methods. This parameter change enables simultaneous analysis of multiple peptides and samples, transforming the process from low-throughput to high-throughput while preserving the accuracy required for reliable immunomonitoring data.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the identification of relevant tumor-associated peptides for vaccine development by providing precise, high-throughput quantification of MHC ligand peptides across different tissue samples, overcoming previous limitations and enabling personalized immunotherapy approaches.
Implementation Method 1
performing an HPLC-MS analysis on said MHC ligand peptides in order to generate a peptide signal therefor
Data Source
Figure 1A~1B
Figure 1C~1D
Figure 2a
AI summary
The invention relates to a method for quantitatively identifying relevant HLA-bound peptide antigens from primary tissue specimens on a large scale without labeling approaches. This method can not only be used for the development of peptide vaccines, but is also highly valuable for a molecularly defined immunomonitoring and the identification of new antigens for any immunotherapeutic strategy in which HLA-restricted antigenic determinants function as targets, such as a variety of subunit vaccines or adoptive T-cell transfer approaches in cancer, or infectious and autoimmune diseases.